"Tagrisso reduced the risk of recurrence or death by 73 percent compared to placebo in stage IB-IIIA lung cancer, which confirmed its clinical benefit as an adjuvant therapy after surgery,” Lee said. “As a result, as of October 2024, Tagrisso remains the only EGFR-TKI approved for adjuvan...
“In March, we launched the first private-sector collaboration with the Korean Foundation for Women and the Korean Association for Lung Cancer to promote early lung cancer screening,” said AstraZeneca Korea Country President Chon Se-whan. “By engaging student ambassadors and experts from various f...
Reports on the recommendation made by a Food and Drug Administration advisory panel to approve the Iressa lung-cancer drug from AstraZeneca PLC in the U.S. as of September 25, 2002.EBSCO_bspWall Street Journal - Eastern EditionLueckSarah...
Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Our plenary data at ASCO show the pioneering role of our medicines in curative-intent lung cancer treatment and highlight progress toward our continued a...
Pushing the boundaries of lung cancer research In addition to the two Presidential Symposia presentations, investigational data being presented at ESMO demonstrate the breadth and depth of AstraZeneca’s commitment to advancing the treatment of lung cancer: ...
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.
LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading. Based on an interim analysis of a Phase 3 trial, the compan...
AstraZeneca said Imfinzi was also recently granted Breakthrough Therapy Designation by the FDA in the same setting, which will help accelerate the regulatory review. Small cell lung cancer is a highly aggressive form of lung cancer. Imfinzi is a human monoclonal antibody, which ...
Since 2014, AstraZeneca has focused on oncology, rolling out several therapies, including Imfinzi, kinase inhibitor Calquence, PARP inhibitor Lynparza and EGFR-targeted med Tagrisso. In lung cancer, Imfinzi, which topped $1.47 billion in sales last year, is under priority review for a new four...
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer 5 December 2024 TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinicall...